U.S. News & World Report’s Best Hospitals guide has ranked Dana-Farber/Brigham and Women’s Cancer Center the top cancer center in New England and fifth overall in the country. The rankings are now available online at www.usnews.com/besthospitals.
Scientists at Dana-Farber Cancer Institute have isolated a new type of energy-burning fat cell in adult humans which they say may have therapeutic potential for treating obesity.
Dana-Farber reports a novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer.
Researchers at Dana-Farber/Children’s Hospital Cancer Center have devised a strategy to directly activate a natural “death” protein, triggering the self-destruction of cells--which could lead to new possibilities for designing cancer drugs.
Scientists at the Dana-Farber/Children’s Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in relapsed and refractory blood cancers.
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.
Scientists have published the first results from the Cancer Cell Line Encyclopedia, a freely available resource that marries deeply detailed cancer genome data with predictors of drug response, information that could lead to refinements in cancer clinical trials and future treatments.
A report from the nation’s leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2004 and 2008. The findings come from the latest Annual Report to the Nation on the Status of Cancer.
The Lung Genomics Research Consortium – an alliance of scientists at five U.S. institutions – has published a new website that makes a broad range of genomic data on chronic lung disease available in a format specifically tailored to investigators’ needs.
Brigham and Women's Hospital and Dana-Farber Cancer Institute researchers have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers might respond to platinum-based chemotherapies.
A six year old Dana-Farber/Children’s Hospital Cancer Center patient, who has been diagnosed with a rare brain tumor went on a “dream date” with Justin Bieber, thanks in part to a Facebook campaign to have her meet the pop star. As important as the date itself, however, is the attention it has focused on atypical teratoid rhabdoid tumor, or AT/RT
Dana-Farber Cancer Institute researchers have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be susceptible to anti-angiogenic drugs. The investigators estimate that the subtype may account for a third of all serous ovarian cancers.
Novel gene abnormalities discovered in a subpopulation of lung and colorectal tumors could potentially identify patients with a good chance of responding to highly specific “targeted” drugs already in use for treating other cancers, scientists report. The genetic alterations – pieces of two genes fused together - showed up in a massive search of the DNA in stored tumor samples of non-small cell lung cancer and colorectal cancer, said researchers from Dana-Farber Cancer Institute and Foundation Medicine, Inc. These specific genetic abnormalities had not been previously linked to the two cancer types.
A Dana-Farber Cancer Institute study suggests that many terminally ill cancer patients do talk with a doctor about their preferences for end-of-life care, but those conversations often occur late in the course of their illness. Furthermore, the conversations tended to be with a hospital-based physician and not their oncologist who has been caring for them.
Genetic specialists at Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) are recommending that children being treated for sarcoma should be offered genetic counseling for Li-Fraumeni syndrome, a rare condition that greatly raises a person’s risk of developing additional cancers.
Treatment with three "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. These risks remain low, but they should be factored in when developing patients’ treatment plans.
World Cancer Day is Saturday, February 4th. Prevention is the theme this year. Dana-Farber expert says simple lifestyle changes can reduce your cancer risk
The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.
Dana-Farber Cancer Institute researchers have mapped out a mechanism by which micronuclei could potentially disrupt the chromosomes within them and produce cancer-causing gene mutations. The findings may point to a vulnerability in cancer cells that could be attacked by new therapies.
Dana-Farber Cancer Institute scientists have isolated a natural hormone that triggers some of the key health benefits of exercise. Irisin, which switches on genes that convert white fat into "good" brown fat, may hold promise as a treatment for diabetes, obesity and perhaps other disorders, including cancer.
With the start of a new year, Dana-Farber Cancer Institute experts are encouraging people to ring in new healthy habits and offer a number of free and low-cost strategies to help people maintain good health and possibly reduce various cancer risks.
Dana-Farber has launched Insight, a blog offering expert commentary on cancer research and care advances and insight on issues and topics relevant to cancer patients. Insight also will feature perspectives on treatment options and provide information that is not available in traditional media outlets.
In an African county lacking any specialists in children’s cancers, a team approach that “twins” Rwandan physicians with Boston-based pediatric oncologists has shown it can deliver expert, curative care to young patients stricken with lymphoma.
Scientists at Dana-Farber Cancer Institute have created a “cocktail” of immune-stimulating peptides they believe could provoke the body’s defenses to attack multiple myeloma in its early “smoldering” phase and slow or prevent the blood cancer.
Dana-Farber Cancer Institute researchers say when the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients.
Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom’s macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.
A therapy involving a natural compound may improve the ability of stem cells from umbilical cord blood to engraft in patients receiving a stem cell transplant for cancer or other diseases, a phase I clinical trial led by Dana-Farber Cancer Institute scientists indicates.
Experts from Dana-Farber Cancer Institute offer some tips to pick festive foods that may even fight cancer.
The most comprehensive search to date of DNA abnormalities in chronic lymphocytic leukemia (CLL) has unearthed several new altered genes that drive this common blood cancer, a finding that could potentially help doctors predict whether an individual patient’s disease will progress rapidly or remain indolent for years.
Researchers at Dana-Farber Cancer Institute have identified a mechanism in mice that triggers inflammation in the liver and transforms normal cells into cancerous ones.
Hormone-blocking therapy for prostate cancer doesn’t raise the risk of fatal heart attacks – as some recent studies had suggested – according to a new report from Dana-Farber/Brigham and Women’s Cancer Center.
Scientists at Dana-Farber Cancer Institute have used IL-2, an immune system stimulant, as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.
Two-drug combination may alleviate radiation sickness in people.
Dana-Farber scientists have devised a test that can predict how effective chemotherapy will be by determining whether tumor cells are "primed" for death. The discovery suggests it may be possible to predict which patients will likely benefit from chemo, as well as to make some chemo more effective.
Dana-Farber and Brigham and Women’s Hospital have launched a research program to scan adult cancer patients’ tumor tissue for nearly 500 cancer mutations in 41 genes. The goal is to build a comprehensive database for research into the genetic makeup of different cancer types and, ultimately, the development of more treatments.
Scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers, a sign that it might contribute to the disease and potentially be a key to diagnosing, preventing, and treating it.
Scientists at Dana-Farber Cancer Institute and Harvard Medical School have found that a common cancer protein leads a second, totally different life in normal adult brain cells: It helps regulates memory formation and may be implicated in Alzheimer's disease.
The American Association for Cancer Research (AACR), releases its AACR Cancer Progress Report 2011, in which its calls on Congress to increase funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Researchers from Dana-Farber and the Scripps Research Institute in Jupiter, Fla., have created prototype drugs that have powerful anti-diabetic effects and are free of dangerous side effects plaguing some current diabetes medications.
Dana-Farber researchers successfully disrupted the function of the gene MYC by tampering with the gene's "on" switch and growth signals in multiple myeloma cells, offering promising strategy for treating myeloma and other cancers driven by the MYC gene.
Dana-Farber Cancer Institute researchers have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of cetuximab. Until now, scientists haven't known why cancers that initially respond to cetuximab become resistant to it, or how to overcome such resistance.
Baruj Benacerraf, MD, who earned a 1980 Nobel Prize in Physiology or Medicine for his groundbreaking research in immunology and led Dana-Farber Cancer Institute through a period of tremendous growth beginning that year, died in Boston on Aug. 2 at the age of 90.
The eon-spanning clock of evolution – the millions of years that generally pass before organisms acquire new traits – belies a constant ferment in the chambers and channels of cells, as changes in genes and proteins have subtle ripple effects throughout an organism. In a study in the July 29 issue of Science, scientists at Dana-Farber Cancer Institute’s Center for Cancer Systems Biology and an international team of colleagues capture the first evidence of the evolutionary process within networks of plant proteins.
Scientists at Dana-Farber Cancer Institute have demonstrated that it’s possible – early in a tumor’s growth – to identify cancer genes that endow the tumor with the ability to metastasize. Testing the technique in melanoma skin cancer, they found six abnormal genes that are both cancer-causing and metastasis-promoting.
In their largest and most comprehensive effort to date, researchers from the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute examined cells from over 100 tumors, including 25 ovarian cancer tumors, to unearth the genes upon which cancers depend. One of these genes, PAX8, is altered in a significant fraction of ovarian tumors — nearly one-fifth of those surveyed in the study.
In a new study, scientists at Dana-Farber Cancer Institute provide the first details of the cancer cell machinery that carries out the hormone’s relentless growth orders.
A difficult-to-treat form of childhood leukemia relies on changes in the structure of DNA – so-called epigenetic changes – to wreak genomic havoc within white blood cells, according to one of two studies conducted by a research team at Children's Hospital Boston and Dana-Farber Cancer Institute. Together with collaborators from a biotechnology company, the same team also showed that a new drug that blocks these changes could deactivate cancer-promoting genes and halt the growth of this cancer.
Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
There has been widespread concern about whether it is safe for women with breast cancer to eat soy. Research concerning its safety has been mixed.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right